G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 22.34 percent increase over losses of $(0.94) per share from
BofA analyst reiterates Buy rating on Tesla, citing near-term catalysts like China breakthrough, Robotaxi event, new product launch, and FSD licensing. Potential for significant earnings benefit and competitive advantage.